BACKGROUND: Hypertension or aortic stenosis causes pressure overload, which evokes hypertrophic myocardial growth. Sustained cardiac hypertrophy eventually progresses to heart failure. Growing evidence indicates that restraining hypertrophy could be beneficial; here, we discovered that FTY-720, an immunomodulator for treating multiple sclerosis, can reverse existing cardiac hypertrophy/fibrosis. METHODS AND RESULTS: Male C57/Bl6 mice underwent transverse aortic constriction (TAC) for 1 week followed by FTY-720 treatment for 2 weeks under continuing TAC. Compared with vehicle-treated TAC hearts, FTY-720 significantly reduced ventricular mass, ameliorated fibrosis, and improved cardiac performance. Mechanistic studies led us to discover that FTY-720 appreciably inhibited nuclear factor of activated T-cells (NFAT) activity. Moreover, we found that in primary cardiomyocytes (rat and human) pertussis toxin (Gi-coupled receptor inhibitor) substantially blocked the antihypertrophic effect of FTY-720. This observation was confirmed in a mouse model of pressure overload. Interestingly, gene array analysis of TAC hearts revealed that FTY-720 profoundly decreased gene expression of a group of matricellular proteins, of which periostin was prominent. Analysis of periostin protein expression in TAC-myocardium, as well as in rat and human cardiac fibroblasts, confirmed the array data. Moreover, we found that FTY-720 treatment or knockdown of periostin protein was able to inhibit transforming growth factor-β responsiveness and decrease collagen expression. CONCLUSIONS: FTY-720 alleviates existing cardiac hypertrophy/fibrosis through mechanisms involving negative regulation of NFAT activity in cardiomyocytes and reduction of periostin expression allowing for a more homeostatic extracellular compartment milieu. Together, FTY-720 or its analogues could be a promising new approach for treating hypertrophic/fibrotic heart disease.
BACKGROUND: Hypertension or aortic stenosis causes pressure overload, which evokes hypertrophic myocardial growth. Sustained cardiac hypertrophy eventually progresses to heart failure. Growing evidence indicates that restraining hypertrophy could be beneficial; here, we discovered that FTY-720, an immunomodulator for treating multiple sclerosis, can reverse existing cardiac hypertrophy/fibrosis. METHODS AND RESULTS: Male C57/Bl6 mice underwent transverse aortic constriction (TAC) for 1 week followed by FTY-720 treatment for 2 weeks under continuing TAC. Compared with vehicle-treated TAC hearts, FTY-720 significantly reduced ventricular mass, ameliorated fibrosis, and improved cardiac performance. Mechanistic studies led us to discover that FTY-720 appreciably inhibited nuclear factor of activated T-cells (NFAT) activity. Moreover, we found that in primary cardiomyocytes (rat and human) pertussis toxin (Gi-coupled receptor inhibitor) substantially blocked the antihypertrophic effect of FTY-720. This observation was confirmed in a mouse model of pressure overload. Interestingly, gene array analysis of TAC hearts revealed that FTY-720 profoundly decreased gene expression of a group of matricellular proteins, of which periostin was prominent. Analysis of periostin protein expression in TAC-myocardium, as well as in rat and human cardiac fibroblasts, confirmed the array data. Moreover, we found that FTY-720 treatment or knockdown of periostin protein was able to inhibit transforming growth factor-β responsiveness and decrease collagen expression. CONCLUSIONS: FTY-720 alleviates existing cardiac hypertrophy/fibrosis through mechanisms involving negative regulation of NFAT activity in cardiomyocytes and reduction of periostin expression allowing for a more homeostatic extracellular compartment milieu. Together, FTY-720 or its analogues could be a promising new approach for treating hypertrophic/fibrotic heart disease.
Authors: Polakit Teekakirikul; Seda Eminaga; Okan Toka; Ronny Alcalai; Libin Wang; Hiroko Wakimoto; Matthew Nayor; Tetsuo Konno; Joshua M Gorham; Cordula M Wolf; Jae B Kim; Joachim P Schmitt; Jefferey D Molkentin; Russell A Norris; Andrew M Tager; Stanley R Hoffman; Roger R Markwald; Christine E Seidman; Jonathan G Seidman Journal: J Clin Invest Date: 2010-09-01 Impact factor: 14.808
Authors: Angela Lorts; Jennifer A Schwanekamp; Troy A Baudino; Elizabeth M McNally; Jeffery D Molkentin Journal: Proc Natl Acad Sci U S A Date: 2012-06-18 Impact factor: 11.205
Authors: Sven-Christian Sensken; Claudia Stäubert; Petra Keul; Bodo Levkau; Torsten Schöneberg; Markus H Gräler Journal: Cell Signal Date: 2008-02-01 Impact factor: 4.315
Authors: Wei Liu; Min Zi; Ronald Naumann; Susanne Ulm; Jiawei Jin; Domenico M Taglieri; Sukhpal Prehar; Junhong Gui; Hoyee Tsui; Rui-Ping Xiao; Ludwig Neyses; R John Solaro; Yunbo Ke; Elizabeth J Cartwright; Ming Lei; Xin Wang Journal: Circulation Date: 2011-11-14 Impact factor: 29.690
Authors: Angela Lorts; Jennifer A Schwanekamp; John W Elrod; Michelle A Sargent; Jeffery D Molkentin Journal: Circ Res Date: 2008-11-26 Impact factor: 17.367
Authors: Robert T Davis; Jillian N Simon; Megan Utter; Paul Mungai; Manuel G Alvarez; Shamim A K Chowdhury; Ahlke Heydemann; Yunbo Ke; Beata M Wolska; R John Solaro Journal: Cardiovasc Res Date: 2015-10-12 Impact factor: 10.787
Authors: David M Ryba; Chad M Warren; Chehade N Karam; Robert T Davis; Shamim A K Chowdhury; Manuel G Alvarez; Maximilian McCann; Chong Wee Liew; David F Wieczorek; Peter Varga; R John Solaro; Beata M Wolska Journal: Circ Heart Fail Date: 2019-11-05 Impact factor: 8.790
Authors: Fu Sang Luk; Roy Y Kim; Kang Li; Daniel Ching; David K Wong; Sunil K Joshi; Isabella Imhof; Norman Honbo; Holly Hoover; Bo-Qing Zhu; David H Lovett; Joel S Karliner; Robert L Raffai Journal: J Cardiovasc Pharmacol Date: 2016-01 Impact factor: 3.105
Authors: Ferenc Boldizsar; Oktavia Tarjanyi; Katalin Olasz; Akos Hegyi; Katalin Mikecz; Tibor T Glant; Tibor A Rauch Journal: Cardiovasc Pathol Date: 2016-05-17 Impact factor: 2.185